GPT and steatosis: In a small, non-randomised study of individuals with ultrasonagraphic steatosis, DDP-IV inhibition was associated with improved glycaemic control and reduced AST and ALT [102] and in a prospective blinded randomised controlled study, 6 months of treatment reduced hepatic triglyceride as measured by MRS [103].